CLINICAL TRIALS PROFILE FOR VIMPAT
✉ Email this page to a colleague
All Clinical Trials for Vimpat
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00237458 ↗ | An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain | Completed | UCB Pharma | Phase 2 | 2001-05-01 | This trial is the follow-on trial to a preceeding open-label trial which included patients with chronic refractory neuropathic pain. It is conducted at one site in the United Kingdom and the patient enrollment is completed. The patients had successfully completed the above mentioned trial and, in the investigator's opinion, would benefit from long-term administration of Lacosamide. After a 1-week run-in phase the patients were uptitrated to their optimal dose and then continued into the maintenance phase. Different pain qualities are assessed by a patient's diary. |
| NCT00401830 ↗ | Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. | Completed | UCB Pharma | Phase 2 | 2006-10-01 | This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome. |
| NCT00440518 ↗ | A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis | Completed | UCB Pharma | Phase 2 | 2007-02-01 | The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines. |
| NCT00485472 ↗ | Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee | Terminated | UCB Pharma | Phase 2 | 2007-03-01 | The purpose of this trial is to evaluate the effectiveness, safety and tolerability of lacosamide (LCM) 400mg/day in treating the signs and symptoms of osteoarthritis of the knee. |
| NCT00520741 ↗ | Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures | Completed | UCB BIOSCIENCES, Inc. | Phase 3 | 2007-08-01 | The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs. |
| NCT00530855 ↗ | Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures | Completed | UCB Pharma | Phase 3 | 2008-02-01 | This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the conversion to monotherapy trial (SP902). |
| NCT00546351 ↗ | Study Evaluating Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Distal Diabetic Neuropathy. | Completed | UCB Pharma | Phase 3 | 2004-05-01 | SP746 (NCT00546351) is a multi-center, open-label, follow-on trial. The purpose of this trial is to assess safety and tolerability of long-term exposure of lacosamide (previously referred to as SPM 927) in subjects with painful distal diabetic neuropathy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Vimpat
Condition Name
Clinical Trial Locations for Vimpat
Trials by Country
Clinical Trial Progress for Vimpat
Clinical Trial Phase
Clinical Trial Sponsors for Vimpat
Sponsor Name
